Abstract 3355
Background
Compared to children, Adolescent and Young Adult (AYA) cancer patients, diagnosed with cancer between 18-39 years old, more often suffer from delay in diagnosis and lack of centralization of care, age-specific expertise and structured follow-up. This group presents with a unique spectrum of cancers with distinctive tumor biology, cancer risk factors, and psychosocial developmental challenges. The potential burden of medical and psychosocial problems could result in compromised quality of life and reduced life expectancy. Given the differences, findings derived from childhood cancer patients cannot be extrapolated to AYA cancer patients. It is imperative for advances in the field of AYA oncology to pool data sources (patient-reported outcomes, clinical, genetic and biological data) across institutions and create large cohorts that include the full range of AYA ages and diagnoses to be able to address the many pressing questions that remain unanswered in this vulnerable population. Therefore, we will create a unique nationwide infrastructure (COMPRAYA) for research into the prevalence, predictive and prognostic markers and underlying mechanisms of early and late medical and psychosocial outcomes, and to facilitate the development and testing of (early) intervention strategies to improve these outcomes for patients (at risk).
Trial design
An observational cohort of 1-year AYA cancer survivors (N = 4000), recruited over 4 years, followed prospectively, will be established. Patients are asked to (1) complete validated patient-reported outcome measures; (2) donate a blood, hair, urine and stool sample; (3) consent for biobanking of tumor tissue and serial clinical data extraction from medical records and Netherlands Cancer Registry; (4) visit an outpatient clinic (vital and phenotypic parameters); (5) be approached for ancillary studies. The established Dutch AYA cancer care network forms an optimal collaborating environment. Next to the COMPRAYA research infrastructure, an online AYA platform will be created together with and for AYA cancer patients where age-specific information, support and interventions will become available.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital.
Funding
KWF Kanker Bestrijding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
6008 - Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: updated results
Presenter: David Cella
Session: Poster Display session 3
Resources:
Abstract
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract